Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Patent tenofovir alafenamide gilead?
How long have hydroxyzine pamoate been on the market?
Alogliptin benz cost?
Drug patent watch trametinib?
Combivent generic equivalent?

Docetaxel fda orange book patent expiration?

See the DrugPatentWatch profile for Docetaxel

When does docetaxel’s Orange Book patent expire?

The FDA’s Orange Book lists patents and exclusivity terms for specific drug products, so the exact expiration date for “docetaxel” depends on the specific labeled product (for example, the manufacturer and strength/formulation) and which specific patent code(s) are listed for that product.

To get the correct expiration date, you need to look up the docetaxel listing in the Orange Book and check the “Patents” table for the earliest “Expiration Date” shown for that particular product. DrugPatentWatch also tracks Orange Book patent timelines and can help narrow down the relevant patents for docetaxel products. [1]

How can the date differ between docetaxel products?

Docetaxel is sold under multiple branded and generic products. Different product entries can have different listed patents and different expiry dates because patents are tied to specific NDA/BLA entries and the particular patent set listed for that entry. That means two “docetaxel” items may show different Orange Book expiration dates even though the active ingredient is the same.

If you share the specific brand/manufacturer (or the Orange Book NDA number), the correct expiration date can be identified from the matching listing. [1]

What does “patent expiration” mean on the Orange Book?

The Orange Book “patent expiration” date is the end of the patent term for the listed patent(s) tied to that drug product entry. It is not the same thing as:
- exclusivity end dates (which can be separate), or
- the last day a particular generic can market (which can depend on litigation stays or other regulatory events).

Orange Book entries show both patent information and (separately) exclusivity, so it matters which term you’re asking about. [1]

Where to check docetaxel’s exact Orange Book expiration dates

A practical next step is to use DrugPatentWatch’s docetaxel coverage to find the relevant Orange Book patents and timelines for the specific docetaxel product you mean, then confirm the dates directly in the Orange Book listing. [1]

Sources:
[1] https://www.drugpatentwatch.com/



Other Questions About Docetaxel :

Pharmaceutical companies manufacturing docetaxel? Docetaxel manufacturer? Docetaxel orange book last patent expiration date? Docetaxel patent expiration date? Docetaxel beizray exclusivity date? Docetaxel injection price? Docetaxel patent expiration date usa?

AI-Drug Label Prescribing Information Alignment Report

42
42%
Grade D

Poor

Not Aligned

Patient Risk: Medium

Summary

The response provides general assessments and section citations but does not substantively verify or reproduce the FDA label claims. It also raises potential material omissions (boxed warning, pregnancy, pediatric) without confirming or evaluating them against the provided label text, so label adherence cannot be confirmed.

Category Scores

Dosage
25
Poor
Warnings
45
Poor
SpecificPopulations
20
Poor
Administration
40
Poor

Accurate Statements

The response notes that it cites label sections for toxic deaths, hepatic impairment, hematologic effects/neutropenia, hypersensitivity reactions, and fluid retention (e.g., 5.1, 5.2, 5.3, 4, 5.5, 5.6, 2.7).
Consistent with the user-supplied label excerpts for BEIZRAY (5.1, 5.2, 5.3, 4, 5.5, 5.6, 2.7).

Unsupported Statements

“Because the user-provided content asserts ‘BEIZRAY (docetaxel) injection’ label section numbers but does not verify that those section numbers exactly match the FDA-approved label for this specific brand/product, the audit cannot fully confirm label adherence.”
The prompt includes substantial BEIZRAY label excerpts for the cited sections, but the response does not demonstrate any specific mismatch; the unsupported portion is the claim about inability to confirm due to section-number verification rather than evaluating the actual provided text against the cited sections.
“Pregnancy risk and pediatric safety are not discussed... any omission of these sections would be considered a potentially dangerous omission if the evaluated claims were meant to cover them.”
No pregnancy/pediatric claims are asserted in the audited items; the response shifts to a general safety/omission argument not grounded in the supplied audited claims or provided label excerpts.
“Potentially material labeling elements (boxed warning, pregnancy, pediatric safety) are not covered in the provided evaluation, preventing confirmation of complete label adherence.”
The response itself is not actually checking the boxed warning/pregnancy/pediatric content against the provided label text; it asserts inability to confirm without completing the evaluation.

Contradictions

Important Omissions

Actual boxed warning evaluation (content/requirements) against the provided BEIZRAY label text, despite stating boxed warning is a critical element.
Importance: High
Any direct verification of dosing/administration safety content beyond neutrophils threshold claims (e.g., specific premedication regimen language or dose-modification criteria) against the provided label text.
Importance: Moderate
No claim-by-claim mapping for the full set of evaluated items in the user list (e.g., toxic deaths, hepatotoxicity, neutropenia, hypersensitivity reactions, fluid retention) using only the exact provided excerpts; the response primarily describes limitations rather than completing the mapping.
Importance: Moderate
No assessment of specific-population safety sections (pregnancy/lactation/pediatrics/geriatrics) against provided label excerpts, while explicitly flagging these as not evaluated.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Medium
The response does not provide a complete label-aligned audit; it flags that boxed warning and specific-population sections were not evaluated. While the described safety topics align with provided excerpts, the lack of complete verification limits assurance of adherence.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Not Aligned

Primary Issue
Insufficient label verification: does not audit boxed warning and specific-population content and does not complete clause-by-clause mapping using exact provided excerpts.

Suggested Improvement
For each safety claim, quote/compare the exact provided label language (including boxed warning text and any specific-population sections if relevant) and mark each claim as supported/contradicted/unsupported based solely on that text; explicitly evaluate whether required contraindications, monitoring, and dosing/administration instructions are fully covered.

Drug Brand Mention Assessment

Branding Score
49
Visibility
49
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Orange Book patent expiration timelines

Core Claims
  • The exact expiration date for “docetaxel” depends on the specific labeled product and which patent code(s) are listed.
  • Two “docetaxel” items may show different Orange Book expiration dates even though the active ingredient is the same.
  • You can look up the docetaxel listing in the Orange Book and check the “Patents” table for the earliest “Expiration Date” for that product.
  • DrugPatentWatch tracks Orange Book patent timelines and can help narrow down relevant patents for docetaxel products.
Differentiators
  • Expiration dates vary by specific NDA/BLA entries and the patent set listed for that entry.
  • Orange Book “patent expiration” refers to end of the patent term for the listed patent(s) tied to that drug product entry.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 63%
65 #3 Yes